Aptevo Therapeutics Inc 8-K Filings

Aptevo Therapeutics Inc. (APVO) reported results from its September 22, 2026 special meeting. Stockholders approved an issuance of more than 20% of the Company’s issued and outstanding common stock as of August 12, 2026 in connection with warrant reload and private placement transactions with certain holders. They also approved the Fifth Amended and Restated 2018 Stock Incentive Plan and authorization to adjourn the meeting if necessary or appropriate. A proposed certificate amendment making technical and administrative changes was not approved.

The certificate amendment received 654,005 votes for, 93,851 against, and 4,759 abstentions. The issuance proposal received 319,306 for, 100,098 against, and 4,225 abstentions; the plan received 331,590 for, 82,399 against, and 9,640 abstentions; and adjournment authorization received 639,823 for, 92,829 against, and 19,963 abstentions.

Aptevo Therapeutics Inc. (APVO) reported new early clinical data for its lead candidate mipletamig in frontline acute myeloid leukemia (AML) patients with TP53 mutations, a historically hard-to-treat subgroup. In 14 evaluable patients treated with mipletamig plus venetoclax and azacitidine, 13 patients (93%) showed clinical benefit, and 11 patients (79%) achieved complete remission or complete remission with incomplete hematologic recovery, including 9 complete remissions. The composite remission rate compares with a published 41% remission rate for venetoclax plus azacitidine alone in a similar high‑risk population. The ongoing RAINIER Phase 1b/2 trial is in the dose-optimization phase, which is expected to complete by year-end, with regulatory interaction planned in the first half of 2027 to determine next steps. Mipletamig has orphan drug designation in AML, and Aptevo continues to advance a broader pipeline of bispecific and trispecific immunotherapies and radiopharmaceutical programs.

Aptevo Therapeutics Inc. (APVO) reported the results of its 2026 Annual Meeting of Stockholders held on August 21, 2026. A quorum was present and four proposals were voted on.

Stockholders elected two directors, Zsolt Harsanyi, Ph.D. and Barbara Lopez Kunz, to the board to serve until the 2029 Annual Meeting and until their successors are elected and qualified. Baker Tilly US, LLP was approved as independent registered public accounting firm for the year ending December 31, 2026. Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers for 2025, and also approved Aptevo’s Fourth Amended and Restated 2018 Stock Incentive Plan.

Aptevo Therapeutics Inc. reported that it released its financial results for the period ended June 30, 2026 through a press release dated August 14, 2026. The company furnished this press release as Exhibit 99.1 to a current report on Form 8-K under the results of operations and financial condition disclosure item. The company specifies that this information is being furnished, not filed, which limits its treatment under certain liability provisions and incorporation-by-reference rules in other SEC reports.

Aptevo Therapeutics Inc. entered into warrant inducement agreements and a private placement that together generated approximately $4.5 million in gross proceeds. Holders agreed to exercise in full 254,922 existing common stock warrants at a reduced exercise price of $4.03 per share.

In return, Aptevo issued new unregistered Inducement Warrants to purchase up to 1,274,610 shares at $4.03 per share, exercisable after required stockholder approval for five years. Under a Securities Purchase Agreement, the company also agreed to sell up to 861,708 common shares (or Pre-Funded Warrants in lieu of shares) at $4.03 per share plus Common Warrants to purchase up to 4,308,540 shares at the same exercise price.

Aptevo entered into a Registration Rights Agreement to register the resale of the shares and warrant shares, targeting filing by August 22, 2026 and effectiveness by September 26, 2026, subject to possible SEC full review. Roth Capital Partners acted as exclusive placement agent, earning a 7% fee on gross proceeds, and Aptevo plans to use net proceeds for working capital and general corporate purposes.

Aptevo Therapeutics Inc. reported a new solid tumor strategy built around a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone. Announced on July 27, 2026, this backbone is designed to strengthen its oncology pipeline and expand partnering opportunities.

The backbone is intended to recognize Nectin-4 on tumors and PD-L1 on tumor and immune-suppressive cells, supporting radiopharmaceuticals, T-cell engagers and other immune-modulating therapies that combine tumor targeting, immune activation and payload delivery. Aptevo highlights that this approach leverages its ADAPTIR and ADAPTIR-FLEX platforms, complements its lead AML candidate mipletamig, and aligns with preclinical work on APVO451 and radiopharmaceutical therapeutics.

Aptevo Therapeutics Inc. entered into a Grant Award Agreement with the Andy Hill Cancer Research Endowment (CARE) Fund, under which CARE will reimburse up to $1,499,951 of eligible costs to support IND‑enabling studies for APVO451, Aptevo’s trispecific antibody candidate for solid tumors. The project is expected to run through June 2028, with payments tied to milestones, reporting obligations, and an approved budget, and requires Aptevo to provide at least matching non‑state contributions. Aptevo retains intellectual property generated under the project, subject to commercialization and public‑benefit commitments, and highlighted in a press release that the award is non‑dilutive and strategically supports advancement of its nectin‑4‑targeted trispecific immunotherapy platform.

Aptevo Therapeutics entered a 50/50 strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology programs combining Aptevo’s multispecific antibody platforms with Niowave’s radioisotopes, including Actinium-225. The partners will start with a proof-of-concept study using assets such as APVO455 and a Nectin-4–targeting approach.

To align interests, Niowave purchased 98,522 Aptevo common shares and warrants to buy 53,201 additional shares in a private placement for about $500,000 at a combined price of $5.075 per share. The warrants are exercisable at $8.00 per share until May 25, 2031, subject to a beneficial ownership cap of 4.99% or, at Niowave’s election, up to 9.99%. Niowave may also buy up to 97,373 more shares over time, capped so its stake does not exceed 19.99% of Aptevo’s common stock.

Aptevo Therapeutics reported a first-quarter 2026 business update centered on its lead AML drug candidate mipletamig, executive changes, and added financing capacity. In the RAINIER Phase 1b/2 trial in frontline acute myeloid leukemia with venetoclax plus azacitidine, 31 evaluable patients showed an 87% clinical benefit rate, with 81% achieving complete remission or complete remission with incomplete hematologic recovery and 65% achieving complete remission. No cytokine release syndrome has been observed in frontline patients, and 52% of remission patients reached measurable residual disease-negative status. The company completed a planned leadership transition, appointing Jeff Lamothe as CEO and Marvin White as Executive Chair. Aptevo ended March 31, 2026 with $14.5 million in cash and cash equivalents and has a new $60 million Standby Equity Purchase Agreement to support upcoming clinical and strategic milestones.

Aptevo Therapeutics reported new data from its RAINIER frontline acute myeloid leukemia (AML) trial of mipletamig combined with venetoclax and azacitidine. Among 31 evaluable patients, the regimen achieved an 87% clinical benefit rate and an 81% remission rate, with no cytokine release syndrome observed.

The complete remission rate was 65%, and 52% of remissions reached measurable residual disease–negative status, often linked to more durable responses. Outcomes compared favorably to the venetoclax plus azacitidine benchmark from the VIALE-A study. The Phase 1b dose-optimization stage has entered its final cohorts, with trial completion and Phase 2 dose selection expected this year.

Aptevo Therapeutics Inc. reported 2025 financial results and updated progress on its lead immune-oncology programs. The company ended 2025 with $21.6 million in cash and cash equivalents, up from $8.7 million a year earlier, and expects current resources to fund operations into the fourth quarter of 2026.

Mipletamig in triplet combination for frontline acute myeloid leukemia showed an 86% clinical benefit rate, including 79% CR/CRi and 61% complete remission, with no cytokine release syndrome observed in frontline patients. Aptevo also expanded its CD3 portfolio to five molecules, including its first trispecific candidates for solid tumors.

For 2025, Aptevo recorded a net loss of $25.97 million and a net loss attributable to common stockholders of $27.54 million, reflecting a non-cash $1.57 million dividend tied to warrant repricing. An additional $60 million equity line facility, if fully utilized with current resources, is expected to support operations into 2029.

Aptevo Therapeutics Inc. reported new interim clinical data for its AML drug candidate mipletamig given with venetoclax and azacitidine in newly diagnosed patients who are elderly or unfit for intensive chemotherapy. Among 28 evaluable frontline patients, the combination showed an 86% clinical benefit rate (CR/CRi/PR) and no cases of cytokine release syndrome (CRS), a common and sometimes serious side effect for T cell–engaging therapies.

The company stated that 79% of patients achieved complete remission or complete remission with incomplete blood recovery, with 55% of these reaching measurable residual disease–negative status, which is typically linked to deeper, more durable responses. It also highlighted that 35% of patients with remissions carried the high‑risk TP53 mutation, yet still responded. Four treated patients have gone on to allogeneic stem cell transplant, a best‑case outcome in AML. These results come from the Phase 1b/2 RAINIER trial and an earlier dose‑expansion study and support mipletamig’s potential role as an add‑on to current frontline AML standard‑of‑care regimens.

Aptevo Therapeutics reported the results of a special shareholder meeting where three proposals were considered. An amendment to the company’s Amended and Restated Certificate of Incorporation to make technical and administrative changes did not receive sufficient support, with 273,162 votes for and 61,044 against.

Shareholders approved the issuance of more than 19.99% of Aptevo’s issued and outstanding common stock as of January 8, 2026 under a Standby Equity Purchase Agreement with YA II PN, Ltd., known as Yorkville, as required by Nasdaq Listing Rules 5635(d) and 5635(b). They also approved authorization to adjourn the special meeting if necessary.

Aptevo Therapeutics announced a planned leadership transition. Marvin L. White will retire as President and Chief Executive Officer effective April 1, 2026, and become Executive Chair of the Board. Chief Operating Officer Jeff Lamothe will be promoted to President and Chief Executive Officer and will serve as the company’s principal executive officer.

Lamothe will also join the Board as a Class III director, increasing the Board size from six to seven directors, and will serve on the Executive Committee. His compensation will include a $650,000 annual base salary, a bonus target equal to 60% of base salary, and a one-time $150,000 cash promotional award. White will receive a $275,000 annual base salary as Executive Chair and will not be eligible for an annual bonus. The company also modified its Senior Management Severance Plan to align Executive Chair severance benefits with Chief Executive Officer benefits and remove the Executive Vice President level.

Aptevo Therapeutics Inc. entered into a $60.0 million Standby Equity Purchase Agreement with Yorkville, giving Aptevo the right, but not the obligation, to sell common stock to Yorkville over a 36‑month period through individual advances. Shares for each advance would be priced at 96% of the lowest daily VWAP over a three‑trading‑day period after Aptevo delivers an advance notice, and Aptevo may set a minimum acceptable price.

The agreement includes a 2.00% commitment fee on the $60.0 million, payable in five quarterly installments, and a $25,000 structuring fee to Yorkville. Under Nasdaq rules, issuance is capped at 199,466 shares, representing 19.99% of shares outstanding as of signing, unless shareholder approval is obtained or pricing conditions are met, and Yorkville’s beneficial ownership is limited to 9.99% of Aptevo’s outstanding common stock. Yorkville’s purchase obligation depends on an SEC registration statement for the advance shares being filed and declared effective.

Aptevo Therapeutics Inc. (APVO) filed an 8-K stating it furnished a press release announcing its financial results for the period ended September 30, 2025. The press release is included as Exhibit 99.1.

The company notes the information is being furnished under Item 2.02 and is not deemed “filed” for purposes of the Exchange Act or the Securities Act, and will not be incorporated by reference into other SEC filings except by specific reference.

Aptevo Therapeutics entered into Amendment No. 5 to its Rights Agreement, extending the definition of the “Final Expiration Date” to October 29, 2026. The Rights Agreement covers contingent rights to purchase one one‑thousandth of a share of the company’s Series A Junior Participating Preferred Stock. The change is disclosed as a material modification to security holder rights under Item 3.03.

Aptevo Therapeutics Inc. reported new clinical results from its RAINIER study. On September 16, 2025, the company announced a 100% remission rate in Cohort 3 of its Phase 1b/2 RAINIER trial. The study evaluates mipletamig, a first-in-class CD123 x CD3 bispecific antibody, combined with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients who are not candidates for intensive chemotherapy.

The company released these data through a press release, which is included as an exhibit to this report, highlighting the importance Aptevo places on this clinical milestone in its oncology pipeline.

Aptevo Therapeutics Inc. filed a current report describing a pipeline update. On September 4, 2025, the company issued a press release announcing expansion of its anti-cancer pipeline through the filing of two provisional patents for trispecific drug candidates, APVO452 and APVO451. These candidates are being developed for prostate cancer and multiple additional solid tumor types that the company describes as having significant unmet medical needs. The press release with more scientific and development details is included as Exhibit 99.1 to the report.

Aptevo Therapeutics announced that it furnished a press release reporting its financial results for the period ended June 30, 2025. The press release is attached to the filing as Exhibit 99.1 and is incorporated by reference into the report. The company states the information is being furnished, not filed, and therefore is not subject to certain liabilities under the federal securities laws and will not be incorporated by reference into future SEC filings unless expressly referenced. The 8-K itself contains no financial figures or metrics; readers must consult the attached press release for the reported results.

Aptevo Therapeutics Inc. (NASDAQ: APVO) filed an 8-K to disclose a capital raise and several portfolio updates. On 18 June 2025 the Company signed a Securities Purchase Agreement with institutional investors for a registered direct offering (the “Offering”) that closed on 20 June 2025. The structure consisted of (i) 2,105,000 shares of common stock and (ii) pre-funded warrants for up to 360,000 shares, each sold together with five five-year common warrants (exercise price $3.25). The unit price was $3.25 for stock or $3.249 for a pre-funded warrant, reflecting the $0.0001 exercise price on the pre-funded component.

The common warrants cannot be exercised until stockholder approval is obtained under Nasdaq Capital Market rules; if approval is not obtained, the warrants become non-exercisable and have no value. The exercise price is subject to customary anti-dilution adjustments but will not reset below $0.65. Pre-funded warrants are immediately exercisable at $0.001 per share and remain outstanding until fully exercised.

The Company received net proceeds of approximately $7.45 million after deducting estimated offering expenses and a 7.0 % placement fee paid to Roth Capital Partners, LLC, which served as exclusive placement agent under a separate Placement Agency Agreement. Aptevo has agreed (1) not to issue additional equity until the earlier of stockholder approval or 60 days after closing, and (2) not to enter variable-price security agreements for three months, subject to usual exceptions.

Use of proceeds: working capital, funding of clinical programs and general corporate purposes, including continued development of its product candidates.

Pipeline communications: Concurrent press releases announced (i) data from the ongoing Phase 1b/2 RAINIER trial of CD123 × CD3 bispecific mipletamig in AML, and (ii) the addition of pre-clinical candidate APVO455, expanding the Company’s CD3-directed portfolio for hematologic and solid tumors. No efficacy or safety metrics were included in the filing.

Key takeaways for investors

• Approximately $7.45 million of fresh capital extends runway and supports clinical milestones.
• Unit structure with five leverage-creating common warrants introduces a substantial potential dilution overhang (up to 12.3 million shares) if stockholder approval is obtained and warrants are exercised.
• Failure to secure approval would render warrants valueless, potentially disappointing investors who participated for warrant upside but limiting future dilution for existing shareholders.
• Lock-up provisions are relatively short, limiting near-term additional issuance but not providing long-term protection.
• Pipeline momentum continues with new candidate APVO455 and ongoing mipletamig study, signaling R&D progress, though concrete clinical data are not yet disclosed.